Botanix Pharmaceuticals Ltd has released a press release.
Ethics Approval for Phase 2 Atopic Dermatitis Study Received
Filed with ASX ·
Watch Botanix Pharmaceuticals' latest callBotanix Pharmaceuticals (ASX:BOT) Q2 2026 Earnings Call · Replay · Mar 2Read the transcript of Botanix Pharmaceuticals (ASX:BOT) Q2 2026 Earnings Call6ix hasn’t read this filing yet.
Botanix Pharmaceuticals Limited on 6ix
Story so far
Earlier from Botanix Pharmaceuticals
- Botanix receives A$4.6m R&D Tax Incentive refund
- First Patient Treated in BTX 1308 Psoriasis Patient Study
- Ethics Approval for BTX 1308 Psoriasis Patient Study Secured
- Botanix BTX 1503 Clinical Trial Update
- FDA Clears Development Path for BTX 1204
Later from Botanix Pharmaceuticals
- Investigators Meeting Completed for BTX 1204 Phase 2 Study
- Permetrex Outperforms Other CBD Topical Products
- Pause In Trading
- Botanix Provides Retraction in Presentation
- Dermatology Industry Leader Joins Botanix
Follow Botanix Pharmaceuticals into a list and get an email when it puts out news.
Follow Botanix Pharmaceuticals